nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Advice about Herbal Therapies
|
|
|
1999 |
34 |
4 |
p. 1 |
artikel |
2 |
Altretamine and Trastuzumab
|
Solimando, Dominic A. |
|
1999 |
34 |
4 |
p. 404-406 |
artikel |
3 |
Basic Bibliographies
|
|
|
1999 |
34 |
4 |
p. 502-507 |
artikel |
4 |
Danger in Making 10-Fold Dosage Strengths Available
|
|
|
1999 |
34 |
4 |
p. 394 |
artikel |
5 |
Data Elements for Immunization Profiles
|
|
|
1999 |
34 |
4 |
p. 1 |
artikel |
6 |
Etanercept
|
Cada, Dennis J. |
|
1999 |
34 |
4 |
p. 462-481 |
artikel |
7 |
Feverfew
|
Chavez, Mary L. |
|
1999 |
34 |
4 |
p. 436-461 |
artikel |
8 |
How to Interpret Immunization Schedules and Records
|
Grabenstein, John D. |
|
1999 |
34 |
4 |
p. 482-492 |
artikel |
9 |
Improved Prescribing Patterns for Elderly Patients with Computerized Drug Utilization Review
|
|
|
1999 |
34 |
4 |
p. 1 |
artikel |
10 |
Medicare Reimbursement: Entering the Era of Prospective Payment for Geriatric Care (Part 1)
|
Vogenberg, F. Randy |
|
1999 |
34 |
4 |
p. 399-403 |
artikel |
11 |
Name Confusion with New COX-2 Inhibitor Ambiguous Abbreviation “EPO” Handwritten Ampersands Misread Avoiding Mix-ups with Hydroxyzine and Hydralazine
|
Cohen, Michael R. |
|
1999 |
34 |
4 |
p. 412-420 |
artikel |
12 |
New Drugs Approved by the FDA New Dosage Forms and Indications Agents Pending FDA Approval Market Withdrawals Major Labeling Changes
|
Baker, Danial E. |
|
1999 |
34 |
4 |
p. 492-501 |
artikel |
13 |
Olanzapine: Psychopharmacology, Clinical Efficacy, and Adverse Effects
|
Falsetti, Andrew E. |
|
1999 |
34 |
4 |
p. 423-436 |
artikel |
14 |
Preventable Methotrexate Toxicity ADRs Related to Ophthalmic Agents; Ophthalmic Adverse Effects Caused by Systemic Drugs ADRs with Antiretroviral Prophylaxis ADRS with Antimalarial Prophylaxis
|
Shuster, Joel |
|
1999 |
34 |
4 |
p. 409-412 |
artikel |
15 |
Use of Large-Dose Gentamicin Regimens in Elderly Men
|
Segarra-Newnham, Marisel |
|
1999 |
34 |
4 |
p. 420-422 |
artikel |